Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

scAAV1.tMCK.NTF3 - Nationwide Children's Hospital/Sarepta Therapeutics

Next Previous
Drug Profile

scAAV1.tMCK.NTF3 - Nationwide Children's Hospital/Sarepta Therapeutics

Alternative Names: AAV1.NT-3 gene therapy - Nationwide Children's Hospital; Neurotrophin-3 gene therapy - Nationwide Children's Hospital; rAAV1.NT-3 gene therapy - Nationwide Children's Hospital

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nationwide Children's Hospital
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Charcot-Marie-Tooth disease

Most Recent Events

  • 23 Mar 2021 scAAV1.tMCK.NTF3 is still in phase I/II trial in Charcot-Marie-Tooth disease in USA (NCT03520751)
  • 27 May 2019 Sarepta Therapeutics plans a clinical trial for Charcot-Marie-Tooth disease in 2019
  • 08 Oct 2018 Nationwide Children’s Hospital and Sarepta Therapeutics enter an option agreement for neurotrophin-3 gene therapy for the treatment of Charcot-Marie-Tooth disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top